In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo
用户k7g3AjDeE8DM
4小时前
9
10
求助中
帖子自动结束时间: 2025-08-01 14:49:09
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.7326/ANNALS-25-01791-JC
文献链接: https://www.acpjournals.org/doi/10.7326/ANNALS-25-01791-JC
其他信息:
出版社: American College of Physicians
作者: Aarti Thakkar; L. Kristin Newby; undefined undefined
全文下载地址: https://www.acpjournals.org/doi/pdf/10.7326/ANNALS-25-01791-JC